stoxline Quote Chart Rank Option Currency Glossary
  
Evelo Biosciences, Inc. (EVLO)
0.06  0.02 (50%)    06-12 12:18
Open: 0.0006
High: 0.06
Volume: 100
  
Pre. Close: 0.04
Low: 0.0006
Market Cap: 1(M)
Technical analysis
2024-06-12 4:21:55 PM
Short term     
Mid term     
Targets 6-month :  0.07 1-year :  0.08
Resists First :  0.05 Second :  0.07
Pivot price 0
Supports First :  0.02 Second :  0
MAs MA(5) :  0.01 MA(20) :  0.01
MA(100) :  0.04 MA(250) :  2.12
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  33.7 D(3) :  11.7
RSI RSI(14): 71.7
52-week High :  13.93 Low :  0
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EVLO ] has closed Bollinger Bands are 98.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.06 - 0.06 0.06 - 0.06
Low: 0 - 0 0 - 0
Close: 0.06 - 0.06 0.06 - 0.06
Company Description

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 07 Jun 2024
Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session - Yahoo Movies UK

Fri, 26 Jan 2024
Evelo Biosciences Shareholders Approve Dissolution Plan - TipRanks.com - TipRanks

Fri, 25 Aug 2023
Evelo Biosciences: May Be Worth A Small Long Position Before Psoriasis Phase 2 Results - Seeking Alpha

Fri, 21 Jul 2023
Evelo Bio (NASDAQ:EVLO) Gains on Sublease Termination with Bio-Rad - TipRanks.com - TipRanks

Tue, 18 Jul 2023
Hedge Fund and Insider Trading News: Elliott Investment Management, Cerberus Capital Management, Astaris Capital ... - Insider Monkey

Tue, 20 Jun 2023
Why Is Evelo Biosciences (EVLO) Stock Up 51% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 19 (M)
Shares Float 17 (M)
Held by Insiders 0.1 (%)
Held by Institutions 12.8 (%)
Shares Short 197 (K)
Shares Short P.Month 156 (K)
Stock Financials
EPS -15.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.42
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -83.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -74 (M)
Levered Free Cash Flow -43 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.05
Price to Sales 0
Price to Cash Flow -0.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android